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Objectives: To collect data about non-controlled prescribing use of daptomycin and its impact
among  Brazilian patients with serious Gram positive bacterial infection, as well as the
efﬁcacy  and safety outcomes.
Materials  and methods: This is a multi-center, retrospective, non-interventional registry
(August  01, 2009 to June 30, 2011) to collect data on 120 patients (44 patients in the ﬁrst
year  and 76 patients in the second year) who had received at least one dose of commercial
daptomycin  in Brazil for the treatment of serious Gram-positive bacterial infection.
Results: Right-sided endocarditis (15.8%), complicated skin and soft tissue infections (cSSTI)-
wound  (15.0%) and bacteremia-catheter-related (14.2%) were the most frequent primary
infections;  lung (21.7%) was the most common site for infection. Daptomycin was used
empirically  in 76 (63.3%) patients, and methicillin-resistant Staphylococcus aureus (MRSA) was
the most common suspected pathogen (86.1%). 82.5% of the cultures were obtained prior to
or shortly after initiation of daptomycin therapy. Staphylococcus spp. – coagulase negative,
MRSA,  and methicillin-susceptible S. aureus were the most frequently identiﬁed pathogens
(23.8%,  23.8% and 12.5%, respectively). The most common daptomycin dose administered
for  bacteremia and cSSTI was 6 mg/kg (30.6%) and 4 mg/kg (51.7%), respectively. The median
duration  of inpatient daptomycin therapy was 14 days. Most patients (57.1%) did not receive
daptomycin  while in intensive care unit. Carbapenem (22.5%) was the most commonly used
antibiotic concomitantly. The patients showed clinical improvement after two days (median)following  the start of daptomycin therapy. The clinical success rate was 80.8% and the overall
rate  of treatment failure was 10.8%. The main reasons for daptomycin discontinuation weresuccessful  end of therapy (75.8%), switched therapy (11.7%), and treatment failure (4.2%).
Daptomycin  demonstrated a favorable safety and tolerability proﬁle regardless of treatment
duration.
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Conclusions: Daptomycin had a relevant role in the treatment of Gram-positive infections in
the clinical practice setting in Brazil.
 13 EIntroduction
Gram-positive bacteria are a major cause of complicated
skin and soft tissue infections (cSSTI) as well as etiologic
agent of bacteremia with or without infective endocardi-
tis,  with Staphylococcus aureus (including methicillin-resistant
[oxacillin-resistant] S. aureus), Streptococcus species, and
Enterococcus species being the most common pathogens.
cSSTI are considered those in deep soft tissue, or requir-
ing  surgical intervention (infected ulcers, burns, major
abscesses), or associated with comorbidities (diabetes mel-
litus,  obesity, immune deﬁciency, underlying venous or
arterial  insufﬁciency).1 Methicillin-resistant S. aureus (MRSA)
and  methicillin-resistant coagulase-negative Staphylococcus
(MR-CoNS) are well-recognized causes of both community-
acquired and healthcare-associated infections.2 MRSA infec-
tions  have risen in the last few years. In Europe, the reported
rate  of MRSA is as low as 5% in Denmark, Finland, Nether-
lands,  and Sweden and as high as above 40% in Greece, Ireland,
Italy,  Malta and the UK.3 In USA,4 MRSA caused 53% of all S.
aureus  healthcare-associated infections reported to NHSN in
2006–2007, ranging from 49.2% of S. aureus SSIs to 65.2% of
S.  aureus catheter-associated urinary tract infections (CAUTI).
In  Brazil, the overall MRSA rate was  31%.5 Coagulase-negative
staphylococci (CoNS) are important etiologic agents of bac-
teremia  among immunocompromised patients, mainly when
they  are using catheters. They are increasingly involved in
infective  endocarditis,6 greatly associated with the use of
intravenous catheters.
Although  vancomycin has been considered the ﬁrst-line
drug  of choice for treating MRSA and MRCoNS, evidence of
clinical  failures are increasing, suggesting that vancomycin
is  losing its clinical and microbiological potency, resulting
in  increased use of novel antibiotics such as daptomycin.7
These poor vancomycin results have been more  evident when
staphylococcal infections are associated to bacteremia.
The objective of the daptomycin registry in Brazil was to
collect  data about non-controlled prescribing use of dapto-
mycin  and its the impact in Brazilian patients with serious
Gram  positive bacterial infection, as well as the efﬁcacy and
safety  outcomes.
Materials  and  methods
EU-CORE was  a multi-center, retrospective, non-
interventional registry over a ﬁve-year (2007–2012) period to
annually collect outcome data on patients who have received
at  least one commercial dose of daptomycin for the treatment
of  serious Gram-positive bacterial infection. Collected data
concerned  patient population, infections, pathogens, adverse
© 20events  (AEs) and clinical outcomes. Brazil participated during
three  years, from 2009 to 2012 and this is the report of the ﬁrst
two  years of participation, from August 01, 2009 to July 31,2010  and from August 01, 2010 to July 31, 2011. During these
two  years, Brazil included 120 patients in the study, being 44
patients  in the ﬁrst year and 76 patients in the second year.
The  sample size of this patient registry is not based on sta-
tistical  considerations. The primary study objectives were  to
characterize and describe the population of patients receiving
daptomycin and the infections and pathogens treated with
daptomycin; to evaluate the clinical outcomes of daptomycin
therapy; to characterize, describe and evaluate AEs in patients
receiving  daptomycin. Data for efﬁcacy assessment were  col-
lected  for clinical outcome assessment, duration of treatment,
time  to clinical improvement, and safety issues (AE/serious AE
[SAE]). The outcome of clinical improvement was  considered
in  the case of partial resolution of clinical signs and symptoms
and/or  when there was  a need for additional antibiotic ther-
apy  at the end of daptomycin therapy; failure was  deﬁned as
inadequate  response to daptomycin therapy or development
of  resistance, worsening or new/recurrent signs and symp-
toms,  or the need to change antibiotic therapy, or a positive
culture  reported at the end of therapy.
The inclusion criteria for a patient record to be eligible
for retrospective data collection and inclusion in the registry
database  were treatment with at least one dose of dapto-
mycin,  having initiated and completed daptomycin therapy
within  the trial timelines, follow-up of at least 30 days after
end  of treatment, all mandatory information available in hos-
pital  ﬁles. Written informed consent was  waived due to the
nature  of study design – registry (retrospective, observational).
Patients who had received daptomycin as part of a controlled
clinical  trial were not eligible for this study.
Although seventeen institutions were initially evaluated
for  participation, only some of them had sufﬁcient time
and  adequate number of patients who met  eligibility crite-
ria  (daptomycin had been recently launched in the Brazilian
market,  on April, 2009). From seven Brazilian institutions that
were  considered for participation in the study, six collected
retrospective clinical data from medical records using a stan-
dardized  clinical research form (CRF) and protocol (approved
by  the health authority and Institutional Review Boards).
All  information collected reﬂected standard practice in each
site  and there was  no intervention or restriction in clinical
practice. Patient data could be recorded into this registry after
a  minimum of 30 days after the end of daptomycin therapy in
order to capture AEs/SAEs. The reasons for premature study
drug  discontinuation, reason for completion of daptomycin
treatment, and antibiotic use after daptomycin treatment
were  recorded. In cases of multiple infections, investigators
entered the type of infection in order of clinical signiﬁcance
(in  order of most to least severe): endocarditis, osteomyeli-
tis,  bacteremia, other [CNS infection, foreign body/prosthetic
infection, metastatic abscess, necrotizing fasciitis, necrotizing
lsevier Editora Ltda.Este é um artigo Open Access sob a licença de CC BY-NC-NDinfection, surgical/non-surgical antibiotic prophylaxis, sep-
tic  arthritis and urinary tract infection/pyelonephritis], cSSTI,
and  uncomplicated skin and soft tissue infection. Safety
 2 0 1 3;1 7(6):647–653  649
a
d
o
m
n
s
c
d
t
S
a
t
v
d
o
h
R
B
T
t
≥
t
i
q
(
(
i
t
(
c
d
t
w
p
s
o
(
l
i
c
M
D
M
f
V
d
o
t
(
p
T
Table 1 – Baseline patients’ characteristics at start of
daptomycin therapy.
Baseline patients characteristics n (%) Total of
patients
Gender 120
Female 48 (40%)
Male 72 (60%)
Age (years)
Mean ± SD 53.3 ± 19.7
Median 55.0
Minimum–maximum 18–96
Age groups (years) 120
18–30 22 (18.3%)
31–50 31 (25.8%)
51–65 29 (24.2%)
66–80 27 (22.5%)
≥81 11 (9.2%)
Body weight, mean, kg (SD) 78.3 ± 19.5 92
Ethnicity 120
White 65 (54.2%)
Black 12 (10%)
Oriental 4 (3.3%)
Other 7 (5.8%)
Unknown 32 (27.7%)
Neutropenia 119
No 118 (99.2%)
Yes 0
Unknown 1 (0.8%)
Renal function
ClCr  < 30 mL/min 4 (9.1%) 44
Serum creatinine, mean (mg/dL) (SD) 1.2 ± 0.7 75
Minimum–maximum (mg/dL) 0–5
Receiving dialysisa 14 (13.5%) 104
Frequent signiﬁcant underlying disease (>7%) 120
Diabetes mellitus 42 (35%)
Arterial hypertension 41 (34.2%)
Valvular heart disease 17 (14.2%)
Fractures/orthopedic diseases 16 (13.3%)
Chronic renal failure 12 (10%)
Congestive heart failure 10 (8.3%)
Cerebrovascular disease 10 (8.3%)
Serum CPK 75
≤1× ULN 50  (66.7%)
>1–2× ULN 20 (26.7%)
>2–5× ULN 4 (5.3%)
>2–5× ULN 0
>10× ULN 1 (1.3%)
SD, standard deviation; ClCr, creatinine clearance; CPK, creatine
phosphokinase; ULN, upper limit of normal.
ab r a z j i n f e c t d i s .
nalysis included all reports of AEs, the severity of which was
etermined  by the investigators. AEs were recorded regardless
f  their relationship to daptomycin therapy.
The CRFs collected the following information: treat-
ent period, demographics, underlying diseases, pregnancy,
eutropenia, antimicrobials, use of other antibiotics and
tatins,  renal function, creatine phosphokinase (CPK) con-
entrations, diagnosis and details of the current infection,
oses  of current antibiotic treatment, duration of inpa-
ient  and/or outpatient treatment, outcomes, AEs and
AEs  occurring between treatment onset and 30 days
fter  last dose of daptomycin, and discharge informa-
ion.
Statistical analysis was  based on pooled data from the indi-
idual  study sites using the SAS® software version 9.3. All
ata  analyses are descriptive and/or exploratory and consist
f  tabulations of the collected data. No pre-deﬁned statistical
ypotheses were  tested.
esults
aseline  patient  demographics  and  clinical  characteristics
he baseline patients’ characteristics at start of daptomycin
herapy are described in Table 1, with 38 (31.7%) patients aged
65  years. Diabetes mellitus and arterial hypertension were
he  most common signiﬁcant underlying diseases, occurring
n  35% and 34.2% of the patients, respectively. Other fre-
uent  underlying comorbidity included valvular heart disease
14.2%)  and fractures/orthopedic diseases (13.3%). Eighteen
15%)  patients were  considered to have community-acquired
nfections because they were out of hospital 48 h prior to
he  onset of starting daptomycin therapy. Most patients
82.5%) did not receive HMG-CoA (-hydroxy--methylglutaryl
oenzyme A) reductase inhibitor (statin) concomitantly with
aptomycin.
RIE  (15.8%), cSSTI-wound (15.0%), catheter-related bac-
eremia  (14.2%) and non-catheter-related bacteremia (10.8%)
ere  the most frequent primary infections for which the
atients  received daptomycin, but patients with surgical
ite  infections (11.6%), non-complicated SSTI (4.2%), and
steomyelitis (3.3%) also were  treated with daptomycin. Lung
21.7%)  was  the most common site for infection, followed by
ower  extremity (15%). Secondary infections were reported
n  12 (10%) patients, mainly bacteremia (catheter and non-
atheter  related) and osteomyelitis.
icrobiology
aptomycin was  used empirically in 76 (63.3%) patients and
RSA  was  the most commonly suspected pathogen (86.1%),
ollowed  by methicillin-sensitive S. aureus (MSSA) (6.9%) and
RE  (4.2%). Most cultures (82.5%) (mainly blood, but also
eep  tissue, needle aspirate, and venous catheter) were
btained prior to or shortly after initiation of daptomycin
herapy. Staphylococcus spp. coagulase negative (23.8%), MRSA
23.8%)  and MSSA (12.5%) were  the most frequently identiﬁed
athogens in cultures. The identiﬁed pathogens are shown in
able  2.Daptomycin was administered after the dialysis in all patients;
all of them were receiving hemodialysis.
Previous  and  concomitant  antibiotic  therapy
When considering the primary infection, 76 (63.3%) patients
had  received previous antibiotic therapy. As seen in Table 3,
the  most frequently used class of antibiotic prior to dap-
tomycin  was  glycopeptides and treatment failure was  the
primary  reason for discontinuation of previous antibi-
otic  therapy. Eighty-two patients (68.3%) used antibiotics
650  b r a z j i n f e c t d i s . 2 0
Table 2 – Identiﬁed pathogens as primary infection.
Identiﬁed pathogen – n (%) Main
pathogen
Second
pathogen
Staphylococcus spp. coagulase
negative
19 (23.8%) 3 (27.3%)
Methicillin-resistant Staphylococcus
aureus
19 (23.8%) 2 (18.2%)
Methicillin-sensitive Staphylococcus
aureus
10  (12.5%) 0 (0%)
Staphylococcus aureus 9 (11.0%) 0 (0%)
Gram negative bacilli 4 (5.0%) 3 (27.3%)
Enterococcus spp. 6 (7.5%) 1 (9.1%)
Staphylococcus epidermidis 4 (5.0%) 1 (9.1%)
Enterococcus faecalis 1 (1.3%) 1 (9.1%)
Gram positive cocci 2 (2.5%) 0 (0%)
Other 2 (2.5%) 0 (0%)
Streptococcus viridans 2 (2.5%) 0 (0%)
Methicillin-sensitive Staphylococcus
aureus  unknown
1 (1.3%) 0 (0%)
Streptococcus spp. 1 (1.3%) 0 (0%)
CPK  levels measured at baseline are shown in Table 1.Total of patients 80 11
concomitantly with daptomycin: carbapenen (22.5%), miscel-
laneous  (20.8%), penicillin (14.2%), cephalosporin (5.8%), and
aminoglycoside (3.3%).
Daptomycin  prescribing  dose
Most common daptomycin dose administered for bacteremia
and  endocarditis was  6 mg/kg and for cSSSI was 4 mg/kg, with
28  (23.3%) patients receiving alternative doses (Table 4). Dap-
tomycin  was  prescribed once a day, in a 30-min infusion, and
was  the ﬁrst line therapy in 44 (36.7%) patients.
In the inpatient setting, the median duration of dapto-
mycin therapy was  14 days (range 2–82 days), usually with
concomitant antibiotics, with 51 (42.9%) patients receiving
daptomycin in an ICU for a median duration of seven days
(range  1–21 days). For patients treated as outpatient (n = 8), the
median  duration of therapy was  30 days (range 5–85 days) and
no  concomitant antibiotic was  used in 93.5% of the patients.
Table 3 – Most frequently (>9%) used antibiotics for the primary
discontinuation.
Antibiotic Patientsa – n (%) Duration,
median days
(range)
Failur
Glycopeptide 28 (23.3%) 4 (1–30) 8 (28.6
Fluoroquinolone 24 (20.0%) 10 (2–46) 23 (95.8
Penicillin 21 (17.5%) 7 (1–28) 11 (52.4
Cephalosporin 20 (16.7%) 6 (1–16) 10 (50.0
Miscellaneous 13 (10.8%) 10 (2–30) 9 (69.2
Carbapenen 11 (9.2%) 8 (2–14) 9 (81.8
a Percentage of the safety population.
b Percentage of the population of patients who received the speciﬁc drug. 1 3;1  7(6):647–653
The  main reason for daptomycin discontinuation was
successful completion of therapy (75.8%), switched therapy
(11.7%)  and treatment failure (4.2%).
Clinical  outcome
The patients showed clinical improvement after a median of
two  days (range 1–29) after the start of daptomycin therapy.
The  rate of clinical success (cure and improvement) was  80.8%
and  the overall rate of treatment failure was 10.8%. All sites
of  infections, except bacteremia, achieved high rates of cure
(Fig.  1).
Safety  and  tolerability
The safety proﬁle of daptomycin was favorable and was
assessed  in all 120 patients included in this trial. Seven
patients (5.8%) had AE and 5 (4.2%) had SAEs like death (n = 4) or
life threatening situations (n = 1). Investigators classiﬁed 2.5%
(n  = 3) of the AEs as possibly related to daptomycin, and per-
manently  discontinued the treatment. The median AE onset
and  resolution was  eight days (range 1–21) and 12 days (range
2–51),  respectively. The AEs probably related to daptomycin
were ventricular asystole, upper gastrointestinal hemorrhage
and  increased CPK.
SAEs  were, with one event of each, endocarditis,
hemorrhagic shock, embolism, ventricular asystole,
hypoxic–ischemic encephalopathy, metabolic encephalo-
pathy, convulsion, acute renal failure, systemic candidiasis,
cerebral ischemia, gastroduodenitis, device related infection,
stress  ulcer, and upper gastrointestinal hemorrhage; and
septic  shock (2 events).
There  was  no change in renal function/status and no
neutropenia during daptomycin therapy. Serum CPK was
measured  at baseline in 75 (62.5%) patients and during the
course  of daptomycin therapy in 73 (61.3%) patients. SerumDuring  therapy, no patient had CPK elevations above 10×
ULN  and one had a CPK elevation between 5 and 10×
ULN.
 infection prior to daptomycin therapy and the reasons for
Reason  for discontinuationb – n (%)
e Infection
resolved
Resisitant or
non-susceptible
Gram-positive
organism
Toxicity/
intolerance
%) 0 (0.0%) 1 (3.6%) 12 (42.9%)
%) 0 (0.0%) 1 (4.2%) 1 (4.2%)
%) 0 (0.0%) 2 (9.5%) 1 (4.8%)
%) 2 (0.0%) 2 (10.0%) 1 (5.0%)
%) 0 (0.0%) 1 (7.7%) 1 (7.7%)
%) 0 (0.0%) 1 (9.1%) 1 (9.1%)
b r a z j i n f e c t d i s . 2 0 1 3;1 7(6):647–653  651
Table 4 – Daptomycin dosing by primary infection type.
Primary infection type – n (%) Initial daptomycin dose
4 mg/kg 6 mg/kg Alternative dosesa
Bacteremia 2 (6.9%) 19 (30.6%) 8 (28.6%)
cSSTI 15 (51.7%) 9 (14.5%) 4 (14.3%)
Right-sided endocarditis 0 (0%) 14 (22.6%) 5 (17.9%)
Other 4 (13.8%) 10 (16.1%) 1 (3.6%)
SSI 6 (20.7%) 4 (6.5%) 4 (14.3%)
Foreign body 1 (3.4%) 5 (8.1%) 4 (14.3%)
Osteomyelitis 1 (3.4%) 1 (1.6%) 2 (7.1%)
Total of patients 29 62 28
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iscussion
his trial reﬂects the experience of six Brazilian sites with dap-
omycin, which is used to treat cSSTI due to Gram-positive
acteria and SAB (S. aureus bacteremia), including RIE, but also
urgical  site infections, osteomyelitis and non-complicated
STI, suggesting that there is an unmet medical need not
ncluded  in label indications. Daptomycin is being used to
reat  other infections caused by other Gram-positive species,
s  cancer9,10 and orthopedic-related infections.11–14 Despite
ost patients being under 65 years (68.3%), they had sev-
ral  comorbidities, most of them had been hospitalized 48 h
efore the start daptomycin and 63.3% had received previous
ntibiotic  therapy, which may  have favored the emergence
f  infections with drug-resistant pathogens as MRSA, MR-
oNS  and VRE. Older patients (>65 years) had good tolerability
nd  clinical outcomes with daptomycin, consistent with the
esults  of other studies.15
As ﬁrst-line treatment, the antibiotics of choice were
lycopeptides (vancomycin), ﬂuoroquinolone, penicillin,
ephalosporin, or carbapenen. Daptomycin was  used as
econd-line treatment in 63.3% of the patients and the
witch  to daptomycin was  consequence of treatment fail-
re,  resistant or non-susceptible Gram-positive bacteria or
oxicity/intolerance. The main cause for discontinuation of
ancomycin  was  toxicity/intolerance and for other antibiotics
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Bacteremia
(n=30)
CSSSI
(n=28)
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(n=19)
Success ¹ Failure
¹ Clinical success: cure or improved outcomes.
Fig. 1 – Treatment outcomes bon.
8.9 in 5.8%; 9.0–9.9 in 4.2%; 10 in 2.5%; and 12 in 0.8%.
was  treatment failure. So, daptomycin has an important role
as  ﬁrst-line therapy for Gram-positive infections.16
Daptomycin 4 mg/kg intravenously every 24 h for 7–14
days  is the gold standard for cSSTI17 and 6 mg/kg intra-
venously every 24 h for bacteremia and RIE.18 However,
23.3% of the patients received alternative dosages, mainly
between 7.0 and 9.9 mg/kg/day, regardless of the severity
of  the infection. In clinical practice, according to infection
severity, there is a trend to use higher doses of dapto-
mycin, with good efﬁcacy without concerns about toxicity.19
Concomitant administration of other antibiotic agents with
daptomycin  was  common practice and aminoglycosides were
among the most frequent with concomitant use in 15% of
patients.20 In Brazil the most frequently used was  carbape-
nen.
The  median treatment duration of inpatient therapy was
14  days (range 2–82 days) in this registry. In a similar trial,
for  those patients receiving prolonged therapy with dapto-
mycin,  there is no report of increased incidence in AEs.20
As there are relatively few treatment options available for
resistant  Gram positive infections that can be used for long
periods  without an increased risk of AEs, daptomycin might,
therefore,  represent a useful option for the treatment of
chronic  complicated infections where extended duration of
therapy  is required, such as osteoarticular or endovascular
infections.20
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Although few Brazilian patients have received dapto-
mycin therapy as outpatient, data indicate that outpatient
parenteral daptomycin is a suitable agent in cases of
selected Gram positive bacterial infections. After a rela-
tively  brief hospitalization, the majority of patients can
complete  at least three fourths of total treatment dura-
tion  outside of the hospital, receiving 2-min daptomycin
injections.21
The clinical outcome was  favorable for daptomycin, as
patients  showed a clinical improvement after a median of
two  days, the overall clinical success rate was 80.8% and the
overall  rate of treatment failure was  10.8%. Only 11.7% of
the  patients switched daptomycin to another antibiotic and
4.2%  stopped due to treatment failure. Based on the results
presented, one can conclude that, unlike glycopeptides, dap-
tomycin  has similar efﬁcacy against both MRSA and MSSA,
making  it an important option for empirical therapy of sus-
pected  S. aureus infections, regardless of methicillin resistance
risk.17,18
The safety proﬁle of daptomycin was  favorable. The AEs
probably  related to daptomycin were  ventricular asystole,
upper  gastrointestinal hemorrhage and increased CPK. Dap-
tomycin  had been associated with reversible CPK elevation
and  skeletal muscle toxicity before the optimization of the
dosing  interval to a once-daily regimen. In clinical trials
with  once-daily dosing, daptomycin-associated CPK eleva-
tions  were  demonstrated in 7% of patients receiving the
6  mg/kg dose, and was  not observed at the 4 mg/kg dose.25,26
The safety and tolerability proﬁle and low overall rates of
clinical  failure were  similar to the rates reported around the
world.20,22,23
Since the use of statins could increase plasma CPK lev-
els  during therapy with daptomycin and statins are known
to  be associated with myopathy, it is recommended to avoid
this  association during daptomycin treatment.8 In our registry,
most  patients (82.5%) did not receive a HMG-CoA reductase
inhibitor with daptomycin.
Although  there was  no change in renal function/status dur-
ing  daptomycin therapy, it is important to remember that
the  dosing interval in patients with severe renal impairment
(ClCr  < 30 mL/min) with or without dialysis should be adjusted
to  q48 h for both approved doses.8,24,25
Many  publications about CORE (2003–2008) and EU-CORE
(2006–2011) results have been published since the ﬁrst report
in  2006. This Brazilian report is similar to an European report
published  in 2011 showing data from the ﬁrst 2.5 years old
daptomycin use.26 In this European report, 1127 patients were
included  in the registry, the most frequent infection diag-
nosed  was  cSSTI (33%), bacteremia (22%), endocarditis (12%)
and  osteomyelitis (6%). Daptomycin was  empirically used in
53% of the patients. S. aureus was  the most frequently isolated
pathogen  (34%), with 52% resistant to methicillin. The over-
all  clinical success rate was  79%, with a clinical failure rate of
<10%  for all infections.
There  are other 35 reports indexed about these 2 stud-
ies,  many  of them showing results from speciﬁc populations,
27such  as, diabetic patients, patients with chronic renal
failure,28 critical care patients,23 patients with hematologi-
cal malignancies,29 surgical site infections,30 all presenting an
overall  success rate between 70% and 90%.
1 1 3;1  7(6):647–653
As the registry is retrospective, non-comparative, non-
blinded  and non-randomized and clinical outcomes are
judged  by the attending clinician, this trial has some limita-
tions  related to data collection. However, data are important
because  reﬂect the clinical practice.
In conclusion, daptomycin has some activity against a
broad  range of Gram positive pathogens, including organisms
that  are resistant to methicillin, vancomycin, and other cur-
rently  available agents. Considering that the most frequently
treated  infections were RIE, cSSTI or bacteremia, for which the
likelihood  of vancomycin failure is high, daptomycin could be
considered a good option for these indications. Therefore, this
ﬁrst-in-class cyclic lipopeptide antibiotic could be considered
an  important option for Brazilian patients.
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